3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
13
Gastrointestinal Stromal Tumors
3
Primary Myelofibrosis
2
Multiple Myeloma
2
Dermatofibrosarcoma
2
Chordoma
2
Carcinoma, Adenoid Cystic
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Thymoma
1
Thrombocythemia, Essential
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sezary Syndrome
1
Seminoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Endometrial Stromal
1
Rhabdomyosarcoma, Embryonal
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pleural Neoplasms
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Osteosarcoma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Interventions
Ipilimumab
29
Nivolumab
23
pembrolizumab
14
incomplete Freund's adjuvant
10
Cyclophosphamide
10
Melphalan
9
Interleukin-2
9
CTLA-4 Antigen
8
tebentafusp
7
sargramostim
7
Temozolomide
7
MART-1 Antigen
7
Dacarbazine
7
Ranibizumab
6
montanide ISA 51
5
fludarabine phosphate
5
fludarabine
5
Sunitinib
5
Radiosurgery
5
Carboplatin
5
Blood Specimen Collection
5
Bevacizumab
5
aldesleukin
4
aflibercept
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
trametinib
3
sotrastaurin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Imatinib Mesylate
×
Dermatologic
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled